Cardiovascular Outcomes of Cholinesterase Inhibitors in Individuals with Dementia: A Meta-Analysis and Systematic Review

Isik, Ahmet T. and Soysal, Pinar and Stubbs, Brendon and Solmi, Marco and Basso, Cristina and Maggi, Stefania and Schofield, Patricia and Veronese, Nicola and Mueller, Christoph (2018) Cardiovascular Outcomes of Cholinesterase Inhibitors in Individuals with Dementia: A Meta-Analysis and Systematic Review. Journal of the American Geriatrics Society, 66 (9). pp. 1805-1811. ISSN 1532-5415

[img] Other (Correspondence)
Other
Restricted to Repository staff only

Download (378kB)
Official URL: https://doi.org/10.1111/jgs.15415

Abstract

Objectives: To evaluate the cardiovascular (CV) effects of acetylcholinesterase inhibitors (AChEIs) in individuals with dementia Design: Systematic review and meta‐analysis. Setting: Two authors independently searched major electronic databases from inception until June 17, 2017, for longitudinal (without a control group) and cohort (with a control group) studies reporting CV outcomes in relation to AChEIs. Randomized controlled trials were excluded because they included relatively healthy subjects. Participants: Individuals with dementia and controls. Measurements: Changes in CV parameters were summarized using standardized mean differences (SMDs) with 95% confidence intervals (CIs). Event rates were used to assess incidence of hypertension and bradycardia. Incidence of CV events in demented patients versus in healthy controls were compared using hazard ratios (HRs). Results: Of 4,588 initial hits, 31 studies including 258,540 individuals with dementia and 2,246,592 controls were analyzed. In longitudinal and open‐label studies, AChEIs were associated with a significantly greater incidence of hypertension (n=1,573, 4%, 95% CI=2–8%, I2=47%) and bradycardia (n=13,703, 2%, 95% CI=1–6%, I2=98%). AChEIs were associated with a decrease in heart rate (SMD=–1.77, 95% CI=–3.58–0.03, I2=78%) and an increase in PR interval (SMD=0.10, 95% CI=0.008–0.19, I2=3%) from baseline. During a median follow‐up of 116 weeks, AChEIs were associated with a significantly lower risk of CV events (stroke, acute coronary syndrome, CV mortality; HR=0.63, 95% CI=0.45–0.88, I2=18%), without a significantly greater risk of bradycardic events (HR=1.40, 95% CI=0.76–2.59, I2=98%). Conclusion: AChEI therapy may be associated with negative chronotropic and hypertensive effects but also with lower risk of CV events.

Item Type: Journal Article
Keywords: acetylcholinesterase inhibitors, bradycardia, hypertension, cardiovascular disease
Faculty: ARCHIVED Faculty of Health, Social Care & Education (until September 2018)
Depositing User: Lisa Blanshard
Date Deposited: 22 Oct 2018 15:26
Last Modified: 14 Nov 2019 15:58
URI: http://arro.anglia.ac.uk/id/eprint/703722

Actions (login required)

Edit Item Edit Item